

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 38580

Title: Microbiota modification by probiotic supplementation reduces colon cancer-associated colitis in mice

Reviewer's code: 01557050

Reviewer's country: Japan

Science editor: Ze-Mao Gong

Date sent for review: 2018-03-17

Date reviewed: 2018-03-22

Review time: 4 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Dr. Mendes and Carnevalheira, et al reported 'Microbiota modification by probiotic supplementation reduces colon cancer-associated colitis in mice'. The article is well-presented. The reviewer has a minor comment. Comments 1. In Results, page 12, line 6, in Figure 4E, the authors should explain how the authors determine the reduction, and how the authors calculate data for the results in Figure 4E. 2. In Discussion, page 12, line 25-26, please correct mistyping.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 38580

Title: Microbiota modification by probiotic supplementation reduces colon cancer-associated colitis in mice

Reviewer's code: 00227403

Reviewer's country: Italy

Science editor: Ze-Mao Gong

Date sent for review: 2018-03-17

Date reviewed: 2018-03-25

Review time: 8 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

In the section abstract each acronym should be explained (see RT-PCR). Considering that the probiotic group presented more tumours of smaller size (<2 mm) ($P = 0.0002$), could it mean that probiotics slow cancer progression instead to reduce cancer development? This issue should be discussed in the section Discussion.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 38580

Title: Microbiota modification by probiotic supplementation reduces colon cancer-associated colitis in mice

Reviewer's code: 00199586

Reviewer's country: Czech Republic

Science editor: Ze-Mao Gong

Date sent for review: 2018-03-17

Date reviewed: 2018-03-27

Review time: 10 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

The authors report an animal study on the effect of probiotic supplementation during the development of an experimental model of colon cancer-associated colitis. Experiment was performed on quite small number of subjects, but message of this study is clear. I agree with the argument, that little is known about the interaction between probiotics, microbiota composition and neoplastic transformation. Author should explain, why they choose *Lactobacillus acidophilus*, *Lactobacillus rhamnosus* and *Bifidobacterium bifidum* mixture for this experiment. Otherwise I support this manuscript for publication.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 38580

Title: Microbiota modification by probiotic supplementation reduces colon cancer-associated colitis in mice

Reviewer's code: 02567669

Reviewer's country: Germany

Science editor: Ze-Mao Gong

Date sent for review: 2018-03-17

Date reviewed: 2018-03-30

Review time: 13 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This is a very interesting and well written paper which deserves publication in the WJG. Only minor comments: 1. Is the title really correct? Or misleading? Colon cancer-associated colitis or colitis-associated colon cancer? Which is the primary event: 1. colitis leading to 2. colon cancer (if the carcinogen is added) or 1. colon cancer and 2. dextran sulfate associated colitis as the secondary phenomenon? 2. The authors should explain the terms alpha diversity and beta diversity (for the reader not so familiar with these analyses). 3. It is correct that the authors build the bridge to human pathology with corresponding data in CRC or ulcerative colitis. Can they give a suggestion which type of probiotic bacteria are most useful for therapy of inflammatory bowel diseases or for prevention of colorectal cancer (difficult question, I know). 4. Did the authors observe any alteration of mucosal histology near the tumours? Is there a transition zone between

only inflamed mucosa and malignant mucosa?